IDEXX Laboratories, Inc. Price & Performance (IDXX)

IDEXX Laboratories stock has recently hovered around $404, close to its 52-week low, reflecting a challenging period for the veterinary diagnostics firm. While several analysts have raised price targets—Bank of America now at $535—others, such as Stifel, have trimmed expectations, highlighting ongoing volatility and cautious optimism for future performance.123

IDEXX Laboratories continues to attract institutional investors, with ownership levels near 88%. Despite a recent dip in share price and mixed analyst ratings, the company’s long-term market prospects remain appealing, particularly as analysts project a potential 27% upside over the next year for the veterinary diagnostics leader.24

IDEXX Laboratories shares have declined in seven of the last ten sessions, with technical signals indicating a potential further drop in the short term. While the stock remains supported near $397, analysts warn of continued volatility, urging investors to monitor for new bottom pivots before considering new positions.56